ArticleJACC. Case reports2020
Safety and Efficacy of Amiodarone in a Patient With COVID-19.
Article in JACC. Case reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 18 citations in OpenAlex.
- Ion channel inhibition with amiodarone or verapamil in symptomatic hospitalized nonintensive-care COVID-19 patients: The ReCOVery-SIRIO randomized trial.Cardiology journal · 2022Trial
- Molecular docking as a tool for the discovery of novel insight about the role of acid sphingomyelinase inhibitors in SARS- CoV-2 infectivity.BMC public health · 2024Review
- Article
- Antiviral activity of amiodarone in SARS-CoV-2 disease.Physiological research · 2022Article
- COVID-19 health policy evaluation: integrating health and economic perspectives with a data envelopment analysis approach.The European journal of health economics : HEPAC : health economics in prevention and care · 2022Article
- Prevalence, Outcomes, and Management of Ventricular Arrhythmias in COVID-19 Patients.Cardiac electrophysiology clinics · 2022Review
- COVID-19 Knowledge Extractor (COKE): A Curated Repository of Drug-Target Associations Extracted from the CORD-19 Corpus of Scientific Publications on COVID-19.Journal of chemical information and modeling · 2021Article
- Update on Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) in SARS-CoV-2 Infection.Pharmaceuticals (Basel, Switzerland) · 2021Article
- COVID-19 Knowledge Extractor (COKE): A Tool and a Web Portal to Extract Drug - Target Protein Associations from the CORD-19 Corpus of Scientific Publications on COVID-19.ChemRxiv : the preprint server for chemistry · 2020Article
- Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2.bioRxiv : the preprint server for biology · 2020Article
- The COVID-19 Pandemic and Cardiovascular Complications: What Have We Learned So Far?JACC. Case reports · 2020Article
- Repurposing Sigma-1 Receptor Ligands for COVID-19 Therapy?Frontiers in pharmacology · 2020Review
- Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2.Frontiers in pharmacology · 2020Article
- Investigating the human protein-host protein interactome of SARS-CoV-2 infection in the small intestine.Gastroenterology and hepatology from bed to bench · 2020Article
- Antiviral effect of amiodarone and its possible role in COVID-19: An appraisal.Indian journal of pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is an urgent need for effective treatments for coronavirus disease-2019 (COVID-19). Amiodarone, like hydroxychloroquine, exerts antiviral actions by interfering with endocytosis and viral replication. Here, to our knowledge, we report the first case of a patient affected by respiratory failure related to COVID-19 who recovered after only supportive measures and a short amiodarone course. (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.